REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
10/20/2025
Back to search
Official data from USPTO
SIGILON THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
SIGILON THERAPEUTICS
ST13
US500000087508764Class
1, 5, 10
Filing
87508764
Registration
6180506
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
59
Latest update
10/22/2025
Trademark type
Word
Nice classes
1, 5, 10
Filing date
06/28/2017
Registration date
10/20/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/20/2020
Last transaction
10/22/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
01/30/2018
First use in commerce
01/30/2018
Drawing code
4
Owner type
03
Owner location
Cambridge, MA
Examiner
MESSICK,TABITHA LEE
Law office
L40
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Sigilon Therapeutics, Inc.
Representatives
John R. Rudolph Eli Lilly and Company
Technical classification
Nice Classes
Class 1Class 5Class 10
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical agents for scientific and research usesmall molecules in the nature of chemical preparations for research and scientific use in the field of cellular therapeutics; reagents for research purposes; reagents for scientific or medical research use
Class 5
Chemicalpharmaceuticalbiopharmaceutical and biomedical agents for medical useagents for medical usein the nature of agents which mitigate the foreign body response; chemical agents for pharmaceutical or medical purposesagents that mitigate the foreign body response; pharmaceutical agents for encapsulating transplanted cells to prevent the risk of rejection from immune attackfor medical purposes; pharmaceutical preparations for the prevention and treatment of fibrosisinflammationcancer and infection; drug delivery agents in the form of coatings for capsules that facilitate the tolerance and delivery of pharmaceutical preparations; chemical agentsdrug delivery agents for encapsulating pharmaceutical agents and cells that facilitate the delivery of a wide range of pharmaceuticals
Class 10
Implants consisting of artificial materials; coatings sold as an integral component of implantable medical devices
Publications
History of USPTO decisions and trademark events.
59 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
03/18/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
03/18/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
03/18/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/18/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/18/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
10/20/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
09/15/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
09/12/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/05/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/05/2020
IUAF
USE AMENDMENT FILED
08/21/2020
EISU
TEAS STATEMENT OF USE RECEIVED
08/21/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
05/22/2020
EX3G
SOU EXTENSION 3 GRANTED
05/20/2020
EXT3
SOU EXTENSION 3 FILED
05/20/2020
EEXT
SOU TEAS EXTENSION RECEIVED
05/20/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
12/24/2019
EX2G
SOU EXTENSION 2 GRANTED
12/20/2019
EXT2
SOU EXTENSION 2 FILED
12/20/2019
EEXT
SOU TEAS EXTENSION RECEIVED
12/20/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
06/28/2019
EX1G
SOU EXTENSION 1 GRANTED
06/26/2019
EXT1
SOU EXTENSION 1 FILED
06/26/2019
EEXT
SOU TEAS EXTENSION RECEIVED
06/26/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/01/2019
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
12/21/2018
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
12/21/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/06/2018
PUBO
PUBLISHED FOR OPPOSITION
11/06/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/17/2018
ALIE
ASSIGNED TO LIE
09/25/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/12/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
09/06/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
09/06/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/06/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/05/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/05/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
03/22/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
03/22/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
03/07/2018
GNRT
NON-FINAL ACTION E-MAILED
03/07/2018
CNRT
NON-FINAL ACTION WRITTEN
03/07/2018
XAEC
EXAMINER'S AMENDMENT ENTERED
02/14/2018
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/14/2018
GNEA
EXAMINERS AMENDMENT E-MAILED
02/14/2018
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/14/2018
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/11/2018
GNRT
NON-FINAL ACTION E-MAILED
01/11/2018
CNRT
NON-FINAL ACTION WRITTEN
01/11/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/21/2017
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/21/2017
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/21/2017
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
10/02/2017
GNRT
NON-FINAL ACTION E-MAILED
10/02/2017
CNRT
NON-FINAL ACTION WRITTEN
10/02/2017
DOCK
ASSIGNED TO EXAMINER
09/26/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2017
NWAP
NEW APPLICATION ENTERED
07/01/2017
Continuous trademark protection
Get notified about every new filing that threatens SIGILON THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.